Introduction to Animal Models of Pulmonary Emphysema

Emphysema is a condition characterized primarily by destruction of alveolar walls, abnormal enlargement of the alveolar spaces, and diminished elastic recoil of the lungs, leading to progressive ventilatory impairment and reduced respiratory function. Animal models of emphysema, induced through exposure to cigarette smoke or administration of elastase (PPE) or papain, can effectively mimic key pathological processes, including alveolar structural damage, chronic inflammation, and impaired pulmonary function.

Service Advantages of the Aniphe BioLab Pulmonary Emphysema Animal Model Platform

Aniphe BioLab’s pulmonary emphysema model platform employs a proprietary composite modeling approach and is supported by a comprehensive assay system, offering standardized, one-stop experimental services with stable and reliable data.

	Modeling advantages A composite modeling approach combining sulfur dioxide, papain, and mechanical overventilation yields a phenotype that closely resembles the clinical picture, with stable model establishment and excellent reproducibility.
	Comprehensive testing It encompasses a wide range of assays, including pulmonary function tests, pathology, flow cytometry, and inflammatory cytokine measurements.
	Reliable quality control Leveraging SPF‑grade environmental conditions, it supports high‑throughput experiments with precise, parallel data.
	Flexible services We offer end-to-end experimental services and can tailor experimental protocols to your specific needs.

Modeling cycle	4–6 weeks
Laboratory animals	Mice and rats of SPF grade
Positive drug	Tiotropium bromide, roflumilast, budesonide, and dexamethasone, among others, can be used to assess bronchodilatory, anti-inflammatory, and lung-protective effects.
Application areas	It is primarily used for investigating the pathogenesis of pulmonary emphysema, screening anti-inflammatory, antifibrotic, and lung‑function‑improving drugs, and evaluating their efficacy; it can also support preclinical validation of novel drug delivery systems and therapeutic strategies.

Construction of an Animal Model of Pulmonary Emphysema

A pulmonary emphysema model was established by combining sulfur dioxide fumigation with airway instillation of papain, further supplemented by mechanical hyperinflation. This multifactorial approach disrupts alveolar wall architecture, inducing characteristic pathological changes such as alveolar enlargement and impaired lung function. The modeling process yields consistent results, with histopathological features that closely resemble those observed in clinical pulmonary emphysema.